Compare LOMA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOMA | MGTX |
|---|---|---|
| Founded | 1926 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2017 | 2018 |
| Metric | LOMA | MGTX |
|---|---|---|
| Price | $11.61 | $11.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.00 | ★ $24.57 |
| AVG Volume (30 Days) | 344.0K | ★ 688.1K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $27.53 | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $7.04 | $6.62 |
| 52 Week High | $13.20 | $15.35 |
| Indicator | LOMA | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 47.40 |
| Support Level | $11.37 | $8.84 |
| Resistance Level | $12.18 | $11.85 |
| Average True Range (ATR) | 0.45 | 0.59 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 42.97 | 28.08 |
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The Group is engaged in the production and distribution of cement, masonry cement, concrete, limestone, and aggregates, operates a railway concession to provide transportation services, and is also engaged in the industrial waste recycling business. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.